The FDA approved it in 2012 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol
Lipoic acid but not dihydrolipoic acid can react with specific sulfhydryl residues of Keap1, causing the release of Nrf2 (34)
Within the study group, 4,144 liraglutide users and 612 semaglutide users reported gastrointestinal issues, compared to 654 among Contrave users
Drip Gym offers a unique Glow formula that combines glutathione with essential vitamins and nutrients for optimal skin health
The Peptide Compliance Crisis In October 2023, the FDA issued warning letters to multiple peptide providers for marketing non-approved peptides as research chemicals while clearly selling them for human use